Thu, May 17, 2012
Wed, May 16, 2012
Tue, May 15, 2012
Mon, May 14, 2012
Sun, May 13, 2012
Sat, May 12, 2012
Fri, May 11, 2012
Thu, May 10, 2012
Wed, May 9, 2012
[ Wed, May 09th 2012 ]: Market Wire
MIT Welcomes New Board Member
Tue, May 8, 2012
Mon, May 7, 2012
Sat, May 5, 2012
Fri, May 4, 2012
Thu, May 3, 2012
[ Thu, May 03rd 2012 ]: Market Wire
Fiscal Year Revenue Guidance

Exelixis Announces May 17th Webcast of Presentation at the Bank of America Merrill Lynch 2012 Health Care Conference


  Copy link into your clipboard //health-fitness.news-articles.net/content/2012/ .. a-merrill-lynch-2012-health-care-conference.html
  Print publication without navigation Published in Health and Fitness on by Market Wire
          🞛 This publication is a summary or evaluation of another publication

SOUTH SAN FRANCISCO, Calif.--([ ])--Exelixis, Inc. (NASDAQ:EXEL) announced today that Michael M. Morrissey, Ph.D., the companyas president and chief executive officer, will present at the Bank of America Merrill Lynch 2012 Health Care Conference at 3:00 p.m. EDT / noon PDT on Thursday, May 17, 2012, in Las Vegas. During the presentation, Dr. Morrissey will discuss the companyas development program and plans for cabozantinib, and review the most recent publicly available data for the compound. He will also provide a general business update.

The presentation will be webcast and may be accessed via the Event Calendar page under Investors at [ www.exelixis.com ].

About Exelixis

Exelixis, Inc. is a biotechnology company committed to developing small molecule therapies for the treatment of cancer. Exelixis is focusing its proprietary resources and development efforts exclusively on cabozantinib (XL184), its most advanced product candidate, in order to maximize the therapeutic and commercial potential of this compound. Exelixis believes cabozantinib has the potential to be a high-quality, broadly-active, differentiated pharmaceutical product that can make a meaningful difference in the lives of patients. Exelixis has also established a portfolio of other novel compounds that it believes have the potential to address serious unmet medical needs, many of which are being advanced by partners as part of collaborations. For more information, please visit the company's web site at [ http://www.exelixis.com ].


Publication Contributing Sources